Related Experiment Videos

Methyldopa-induced hemolytic anemia in a 15 year old presenting as near-syncope

J S Naidorf1, J M Kennedy, J W Becher

  • 1Department of Emergency Medicine, Osteopathic Medical Center of Philadelphia.

Insights

Methyldopa can cause autoimmune hemolytic anemia, a rare but serious condition. This case highlights the importance of recognizing this drug-induced anemia in pediatric patients presenting with symptoms like near-syncope.

Area of Science:

  • Pediatric Hematology
  • Clinical Toxicology
  • Immunology

Background:

  • Methyldopa is an antihypertensive medication prescribed for adults and rarely for children.
  • Autoimmune hemolytic anemia (AIHA) is a known adverse effect of methyldopa in a small patient subset.
  • Early diagnosis and management are crucial for favorable outcomes.

Observation:

  • A 15-year-old male presented with near-syncope seven weeks after intravenous methyldopa treatment for trauma.
  • Laboratory findings included severe anemia (hemoglobin 3 g/dL), a positive Coombs' test, and a warm autoantibody.
  • The patient's presentation mimicked other causes of anemia and syncope.

Findings:

  • The patient was diagnosed with methyldopa-induced autoimmune hemolytic anemia.
  • Treatment with blood transfusion and corticosteroids led to complete clinical recovery.
  • The positive Coombs' test and presence of a warm autoantibody confirmed the autoimmune mechanism.

Implications:

  • Emergency physicians must consider methyldopa-induced AIHA in pediatric patients with unexplained anemia and relevant drug history.
  • Prompt recognition and appropriate management can prevent severe complications and ensure patient recovery.
  • This case underscores the need for vigilance regarding drug-induced hematologic disorders in children.

Related Concept Videos